$AnaptysBio (ANAB.US)$ NEWS Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) Positive Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab Positive safety and tolerability profile with no treatment-related serious adverse events reported Low incidence ...
AnaptysBio股票讨论
NEWS
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
Positive
Significant improvement in skin clearance for patients receiving imsidolimab in the Phase 3 trials
Excellent maintenance of skin clearance with no flares in patients on monthly maintenance dosing of imsidolimab
Positive safety and tolerability profile with no treatment-related serious adverse events reported
Low incidence ...
资讯
Anaptys将从与Sagard修改后的协议中获得5000万美元的限制性无追索权益金,以换取额外的Jemperli版税
$CG Oncology (CGON.US)$第三阶段
$美国联合医疗 (UTHR.US)$第三阶段
$美国联合医疗 (UTHR.US)$第三阶段
$BioCardia (BCDA.US)$第三阶段
$Insmed (INSM.US)$第三阶段
$GlycoMimetics (GLYC.US)$第三阶段
$Annexon (ANNX.US)$第三阶段
$Lipocine (LPCN.US)$第三阶段
$FibroGen (FGEN.US)$第三阶段
$乌龙制药 (URGN.US)$第三阶段
$Lyra Therapeutics (LYRA.US)$第三阶段
$Citius Pharmaceuticals (CTXR.US)$第三阶段
$Jaguar Health (JAGX.US)$ Phas...
$Intra-Cellular Therapies (ITCI.US)$第三阶段
$CG Oncology (CGON.US)$第三阶段
$和黄医药 (HCM.US)$第三阶段
$Viracta Therapeutics (VIRX.US)$第三阶段
$GlycoMimetics (GLYC.US)$第三阶段
$Annexon (ANNX.US)$第三阶段
$Lipocine (LPCN.US)$第三阶段
$FibroGen (FGEN.US)$第三阶段
$乌龙制药 (URGN.US)$第三阶段
$Lyra Therapeutics (LYRA.US)$第三阶段
$Citius Pharmaceuticals (CTXR.US)$第三阶段
$Marinus Pharmaceuticals (MRNS.US)$第3阶段
$BioCardia (BCDA.US)$ 第三阶段...
暂无评论